Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for ...
| Metric Name | Value | Trend | |
|---|---|---|---|
| Dividend Yield | 4.1% | ||
| P/E Ratio | 18.5x | ||
| Revenue | 4.857 B | ||
| Net Income to Company | 370.8 M |
| EII | Peers | Sector | |
|---|---|---|---|
Market Cap | 6.714 B | 10.164 B | 55.584 M |
Price % of 52 Week High | 59.4% | 79.5% | 59.8% |
Dividend Yield | 4.1% | 0.7% | 0.0% |
Shareholder Yield | 2.0% | 2.1% | -0.7% |
1 Year Price Total Return | -33.2% | -7.5% | -13.6% |
Beta (5 Year) | -0.16 | 0.28 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Mar-23 | Mar-24 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 5,169 | 4,542 | 4,857 | 1,142 | 1,326 |
| Operating Income | 267 | 270 | 404 | 39 | 192 |
| Net Profit | 385 | 260 | 361 | 38 | 146 |
| Diluted EPS | 1.34 | 0.91 | 1.27 | 0.13 | 0.52 |
| EBITDA | 545 | 511 | 650 | 103 | 254 |
| Balance Sheet | |||||
| Cash & ST Invest. | 1,856 | 1,866 | 1,787 | 1,830 | 1,787 |
| Current Assets | 4,320 | 4,427 | 4,669 | 4,247 | 4,669 |
| Total Assets | 8,772 | 8,534 | 8,790 | 8,424 | 8,790 |
| Current Liabilities | 2,076 | 1,864 | 2,341 | 1,785 | 2,341 |
| Total Liabilities | 3,061 | 3,030 | 3,280 | 3,010 | 3,280 |
| Total Equity | 5,712 | 5,504 | 5,511 | 5,414 | 5,511 |
| Total Debt | 876 | 976 | 1,344 | 1,068 | 1,344 |
| Cash Flow Statement | |||||
| Cash Flow Operations | (12) | 343 | 116 | 56 | (0.52) |
| Cash From Investing | (158) | (155) | (11) | (41) | 2.83 |
| Cash From Financing | (170) | (139) | (206) | 49 | 55 |
| Free Cash Flow | (169) | 255 | 42 | 46 | (18) |